Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.47 |
| ▸ | NPY1R | P25929 | 9/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.47 |
| ▸ | NPY2R | P49146 | 5/20 | 0.47 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31621731 | 0.97 | NPY4R (0.52) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL31415957 | 0.93 | NPY4R (0.49) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL16432550 | 0.92 | NPY4R (0.48) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL16432553 | 0.92 | NPY4R (0.48) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL7159410 | 0.92 | NPY4R (0.53) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL27712094 | 0.92 | NPY4R (0.53) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL7098633 | 0.92 | NPY4R (0.53) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL29492567 | 0.92 | NPY4R (0.53) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL29492562 | 0.92 | NPY4R (0.53) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL31696331 | 0.91 | NPY4R (0.51) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12540349-B2 | Horseshoe crab factor B variant | SEIKAGAKU CORPORATION (JP) | 2026-02-03 | — | — | US | disclosed |
| US-20260014211-A1 | METHODS AND COMPOSITIONS FOR INCREASING BACTERIAL ENGRAFTMENT AND POPULATIONS IN THE GUT MICROBIOME | UNIV CHICAGO (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4488372-A2 | METHOD FOR ENHANCING SENSITIVITY OF ENDOTOXIN MEASURING AGENT | Seikagaku Corporation (JP) | 2025-01-08 | — | — | EP | disclosed |
| WO-2024020466-A1 | METHODS AND COMPOSITIONS FOR INCREASING BACTERIAL ENGRAFTMENT AND POPULATIONS IN THE GUT MICROBIOME | THE UNIVERSITY OF CHICAGO (US) | 2024-01-25 | — | — | WO | disclosed |
| CN-110366592-B | Limulus factor B modification | 生化学工业株式会社 | 2024-01-23 | — | — | CN | disclosed |
| EP-3591049-B1 | HORSESHOE CRAB FACTOR B VARIANT | SEIKAGAKU KOGYO CO LTD (JP) | 2023-11-22 | — | — | EP | disclosed |
| US-20230193349-A1 | HORSESHOE CRAB FACTOR B VARIANT | SEIKAGAKU CORPORATION (JP) | 2023-06-22 | — | — | US | disclosed |
| CN-115697069-A | Hypoallergenic recombinant milk proteins and compositions comprising the same | 完美日股份有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-11499177-B2 | Horseshoe crab factor B variant | SEIKAGAKU CORPORATION (JP) | 2022-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540349-B2 | Horseshoe crab factor B variant | RNGTT, UPF1, F13B | NPY4R 2383/4885NPY1R 2519/4885NPY5R 3716/4885 |
| US-20260014211-A1 | METHODS AND COMPOSITIONS FOR INCREASING BACTERIAL ENGRAFTMENT AND POPULATIONS IN THE GUT MICROBIOME | FABP2, CD74, SLC10A2 | NPY4R 2863/4885NPY1R 2422/4885NPY5R 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.